Geoffrey Mackay Sells 14,000 Shares of Avrobio Inc (NASDAQ:AVRO) Stock

Avrobio Inc (NASDAQ:AVRO) insider Geoffrey Mackay sold 14,000 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $27.25, for a total transaction of $381,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ:AVRO traded up $0.48 on Friday, hitting $19.01. 136,458 shares of the company’s stock were exchanged, compared to its average volume of 181,369. Avrobio Inc has a 52 week low of $11.85 and a 52 week high of $53.70. The stock has a market capitalization of $458.10 million and a PE ratio of -5.25.

Avrobio (NASDAQ:AVRO) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.10). As a group, research analysts expect that Avrobio Inc will post -2.77 EPS for the current year.

Several equities research analysts recently commented on AVRO shares. Cowen reaffirmed a “buy” rating on shares of Avrobio in a research report on Thursday. HC Wainwright set a $40.00 price target on shares of Avrobio and gave the stock a “buy” rating in a research report on Monday, April 22nd. Janney Montgomery Scott initiated coverage on shares of Avrobio in a research report on Friday, April 5th. They set a “buy” rating and a $24.42 price target on the stock. Zacks Investment Research raised shares of Avrobio from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Tuesday, January 15th. Finally, Leerink Swann cut their price target on shares of Avrobio from $27.00 to $19.00 and set a “market perform” rating on the stock in a research report on Thursday, January 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $31.06.

Institutional investors have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can acquired a new position in shares of Avrobio during the 4th quarter worth about $34,000. Legal & General Group Plc acquired a new position in shares of Avrobio during the 3rd quarter worth about $48,000. BNP Paribas Arbitrage SA acquired a new position in shares of Avrobio during the 1st quarter worth about $59,000. New York State Common Retirement Fund acquired a new position in shares of Avrobio during the 4th quarter worth about $113,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Avrobio during the 4th quarter worth about $181,000. Institutional investors own 69.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/insider-selling-avrobio-inc-avro-insider-sells-381500-00-in-stock.html.

About Avrobio

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Featured Story: What Does a Sell-Side Analyst Rating Mean?

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.